Study of VS-7375 with cetuximab for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug combination for people with a specific KRAS mutation in pancreatic cancer. It aims to see if the treatment can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that has spread or cannot be removed by surgery.
- Your tumor has a specific genetic change called KRAS G12D (this is confirmed by a test).
- You have not had more than one previous treatment for advanced disease, or you are starting treatment for the first time.
- You are generally healthy and able to care for yourself (ECOG score 0 or 1).
- You have normal organ function and can swallow pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new experimental drug, RNK08954, for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and can help shrink or slow the cancer.
This trial tests a new targeted pill, VS-7375, for people with a specific type of advanced colorectal cancer called KRAS G12D. It's for those who either haven't had treatment yet or whose cancer has worsened after prior therapy.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
This study tests a new drug (GFH276) combined with either cetuximab or chemotherapy for people with advanced solid tumors or pancreatic cancer that have a specific genetic change (RAS mutation). The goal is to see if this combination can shrink tumors or slow their growth.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.